Colorectal Cancer Metastatic, Liver Cancer, Liver Diseases, Liver Metastases, Metastases to Liver, Neoplasms
Conditions
Keywords
Liver Metastases; Metastatic Colorectal Cancer
Brief summary
This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
Interventions
PROCEDUREStandard of Care for Metastatic Liver Cancer
In this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions.
Sponsors
Anhui Provincial Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
1. Patients with histologically or radiologically confirmed metastatic liver cancer. 2. Age ≥ 18 years. 3. Patients who have voluntarily signed the informed consent form. 4. Patients with complete baseline clinical data.
Exclusion criteria
1. Patients with primary liver cancer (e.g., hepatocellular carcinoma). 2. Patients with other malignant tumors that may interfere with the evaluation of liver metastasis. 3. Patients who have previously participated in other interventional clinical trials. 4. Patients with severe cognitive disorders or communication barriers that prevent informed consent. 5. Patients with incomplete or missing key clinical data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Up to 10 years | The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival | Up to 10 years | Description: The time interval from the date of enrollment (or initial treatment) to the date of the first documented disease progression (local recurrence or distant metastasis) or death from any cause, whichever occurs first. |
| Treatment-Related Adverse Events | Within 90 days post-treatment | The incidence and severity of postoperative complications or treatment-related adverse events, graded according to the Clavien-Dindo classification (for surgical complications) or CTCAE (Common Terminology Criteria for Adverse Events) version 5.0. |
Countries
China
Contacts
CONTACTJizhou Wang, MD PhD
CONTACTLianxin Liu, MD PhD
Outcome results
None listed